ÂÜÀòÂÒÂ×

Helen Tayton-Martin, currently the Chief Business Officer at Adaptimmune since July 2008, previously held positions such as Chief Operating Officer at the same company. With experience in various roles in business development and corporate development, Helen has also served as a Non-Executive Director at Trillium Therapeutics Inc. and held positions at Avidex Ltd, Allevia AG, London Technology Network, and Technomark Consulting Services Ltd. Helen obtained an Executive MBA from London Business School and a Doctor of Philosophy (PhD) in Molecular Immunology from the University of Bristol.